Clinical characteristics and outcomes of Langerhans cell histiocytosis at a single institution in Thailand: a 20-year retrospective study

[1] Allen CE, Li L, Peters TL, Leung H-CE, Yu A, Man T-K, et al. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010; 184:4557–67. AllenCE LiL PetersTL LeungH-CE YuA ManT-K Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells J Immunol 2010 184 4557 67 10.4049/jimmunol.0902336314267520220088 Search in Google Scholar

[2] Badalian-Very G, Vergilio J-A, Degar BA, Rodriguez-Galindo C, Rollins BJ. Recent advances in the understanding of Langerhans cell histiocytosis. Br J Haematol. 2012; 156:163–72. Badalian-VeryG VergilioJ-A DegarBA Rodriguez-GalindoC RollinsBJ Recent advances in the understanding of Langerhans cell histiocytosis Br J Haematol 2012 156 163 72 10.1111/j.1365-2141.2011.08915.x22017623 Search in Google Scholar

[3] Héritier S, Emile J-F, Barkaoui M-A, Thomas C, Fraitag S, Boudjemaa S, et al. BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy. J Clin Oncol. 2016; 34:3023–30. HéritierS EmileJ-F BarkaouiM-A ThomasC FraitagS BoudjemaaS BRAF mutation correlates with high-risk Langerhans cell histiocytosis and increased resistance to first-line therapy J Clin Oncol 2016 34 3023 30 10.1200/JCO.2015.65.9508532108227382093 Search in Google Scholar

[4] Kobayashi M, Tojo A. Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment. Cancer Sci. 2018; 109:3707–13. KobayashiM TojoA Langerhans cell histiocytosis in adults: advances in pathophysiology and treatment Cancer Sci 2018 109 3707 13 10.1111/cas.13817627208030281871 Search in Google Scholar

[5] Bhatia P, Singh M, Sharma M, Sharma A, Kakkar N, Radhika S, et al. BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival. Blood Cells Mol Dis. 2020; 82:102356. doi: 10.1016/j.bcmd.2019.102356 BhatiaP SinghM SharmaM SharmaA KakkarN RadhikaS BRAF V600E mutation in childhood Langerhans cell histiocytosis correlates with multisystem disease and poor survival Blood Cells Mol Dis 2020 82 102356 10.1016/j.bcmd.2019.102356 32171112 Open DOISearch in Google Scholar

[6] Ribeiro KB, Degar B, Antoneli CB, Rollins B, Rodriguez-Galindo C. Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2015; 62:982–7. RibeiroKB DegarB AntoneliCB RollinsB Rodriguez-GalindoC Ethnicity, race, and socioeconomic status influence incidence of Langerhans cell histiocytosis Pediatr Blood Cancer 2015 62 982 7 10.1002/pbc.2540425586293 Search in Google Scholar

[7] Salotti JA, Nanduri V, Pearce MS, Parker L, Lynn R, Windebank KP. Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland. Arch Dis Child. 2009; 94:376–80. SalottiJA NanduriV PearceMS ParkerL LynnR WindebankKP Incidence and clinical features of Langerhans cell histiocytosis in the UK and Ireland Arch Dis Child 2009 94 376 80 10.1136/adc.2008.14452719060008 Search in Google Scholar

[8] Bidwell SS, Peterson CC, Demanelis K, Zarins KR, Meza R, Sriplung H, et al. Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990–2011. Pediatr Blood Cancer. 2019; 66:e27428. doi: 10.1002/pbc.27428 BidwellSS PetersonCC DemanelisK ZarinsKR MezaR SriplungH Childhood cancer incidence and survival in Thailand: A comprehensive population-based registry analysis, 1990–2011 Pediatr Blood Cancer 2019 66 e27428 10.1002/pbc.27428 647802830168253 Open DOISearch in Google Scholar

[9] Wiangnon S, Kamsa-Ard S, Jetsrisuparb A, Sriplung H, Sontipong S, Sumitsawan Y, Martin N. Childhood cancer in Thailand: 1995–1997. Asian Pac J Cancer Prev. 2003; 4:337–43. WiangnonS Kamsa-ArdS JetsrisuparbA SriplungH SontipongS SumitsawanY MartinN Childhood cancer in Thailand: 1995–1997 Asian Pac J Cancer Prev 2003 4 337 43 Search in Google Scholar

[10] Rodriguez-Galindo C, Allen CE. Langerhans cell histiocytosis. Blood. 2020; 135:1319–31. Rodriguez-GalindoC AllenCE Langerhans cell histiocytosis Blood 2020 135 1319 31 10.1182/blood.201900093432106306 Search in Google Scholar

[11] Allen CE, Merad M, McClain KL. Langerhans-cell histiocytosis. N Engl J Med. 2018; 379:856–68. AllenCE MeradM McClainKL Langerhans-cell histiocytosis N Engl J Med 2018 379 856 68 10.1007/978-0-387-89839-1_24 Search in Google Scholar

[12] Monsereenusorn C, Rodriguez-Galindo C. Clinical characteristics and treatment of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 2015; 29:853–73. MonsereenusornC Rodriguez-GalindoC Clinical characteristics and treatment of Langerhans cell histiocytosis Hematol Oncol Clin North Am 2015 29 853 73 10.1016/j.hoc.2015.06.00526461147 Search in Google Scholar

[13] Haupt R, Minkov M, Astigarraga I, Schääfer E, Nanduri V, Jubran R, et al. Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years. Pediatr Blood Cancer. 2013; 60:175–84. HauptR MinkovM AstigarragaI SchääferE NanduriV JubranR Langerhans cell histiocytosis (LCH): guidelines for diagnosis, clinical work-up, and treatment for patients till the age of 18 years Pediatr Blood Cancer 2013 60 175 84 10.1002/pbc.24367455704223109216 Search in Google Scholar

[14] Jessop S, Crudgington D, London K, Kellie S, Howman-Giles R. FDG PET-CT in pediatric Langerhans cell histiocytosis. Pediatr Blood Cancer. 2020; 67:e28034. doi: 10.1002/pbc.28034 JessopS CrudgingtonD LondonK KellieS Howman-GilesR FDG PET-CT in pediatric Langerhans cell histiocytosis Pediatr Blood Cancer 2020 67 e28034 10.1002/pbc.28034 31599488 Open DOISearch in Google Scholar

[15] Monsereenusorn C, Minkov M, Rodriguez-Galindo C. Current treatment of Langerhans cell histiocytosis. Expert Opin Orphan Drugs. 2016; 4:1057–68. MonsereenusornC MinkovM Rodriguez-GalindoC Current treatment of Langerhans cell histiocytosis Expert Opin Orphan Drugs 2016 4 1057 68 10.1080/21678707.2016.1230058 Search in Google Scholar

[16] Krooks J, Minkov M, Weatherall AG. Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up. J Am Acad Dermatol. 2018; 78:1047–56. KrooksJ MinkovM WeatherallAG Langerhans cell histiocytosis in children: diagnosis, differential diagnosis, treatment, sequelae, and standardized follow-up J Am Acad Dermatol 2018 78 1047 56 10.1016/j.jaad.2017.05.06029754886 Search in Google Scholar

[17] Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008; 111:2556–62. GadnerH GroisN PotschgerU MinkovM AricoM BraierJ Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification Blood 2008 111 2556 62 10.1182/blood-2007-08-10621118089850 Search in Google Scholar

[18] Gadner H, Minkov M, Grois N, Pötschger U, Thiem E, Arico M, et al. Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis. Blood. 2013; 121:5006–14. GadnerH MinkovM GroisN PötschgerU ThiemE AricoM Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis Blood 2013 121 5006 14 10.1182/blood-2012-09-45577423589673 Search in Google Scholar

[19] Imashuku S, Kinugawa N, Matsuzaki A, Kitoh T, Ohki K, Shioda Y, et al.; Japan LCH Study Group. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems. Int J Hematol. 2009; 90:506–12. ImashukuS KinugawaN MatsuzakiA KitohT OhkiK ShiodaY Japan LCH Study Group Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems Int J Hematol 2009 90 506 12 10.1007/s12185-009-0420-419779766 Search in Google Scholar

[20] Gao Y-J, Su M, Tang J-Y, Pan C, Chen J. Treatment outcome of children with multisystem Langerhans cell histiocytosis: the experience of a single children's hospital in Shanghai, China. J Pediatr Hematol Oncol. 2018; 40:e9–12. doi: 10.1097/MPH.0000000000001016 GaoY-J SuM TangJ-Y PanC ChenJ Treatment outcome of children with multisystem Langerhans cell histiocytosis: the experience of a single children's hospital in Shanghai, China J Pediatr Hematol Oncol 2018 40 e9 12 10.1097/MPH.0000000000001016 29200145 Open DOISearch in Google Scholar

[21] Su M, Gao YJ, Pan C, Chen J, Tang JY. Outcome of children with Langerhans cell histiocytosis and single-system involvement: a retrospective study at a single center in Shanghai, China. Pediatr Hematol Oncol. 2018; 35:385–92. SuM GaoYJ PanC ChenJ TangJY Outcome of children with Langerhans cell histiocytosis and single-system involvement: a retrospective study at a single center in Shanghai, China Pediatr Hematol Oncol 2018 35 385 92 10.1080/08880018.2018.154581430693828 Search in Google Scholar

[22] Morimoto A, Shioda Y, Imamura T, Kudo K, Kitoh T, Kawaguchi H, et al.; Japan LCH Study Group. Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2018; 108:192–8. MorimotoA ShiodaY ImamuraT KudoK KitohT KawaguchiH Japan LCH Study Group Intensification of induction therapy and prolongation of maintenance therapy did not improve the outcome of pediatric Langerhans cell histiocytosis with single-system multifocal bone lesions: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study Int J Hematol 2018 108 192 8 10.1007/s12185-018-2444-029594922 Search in Google Scholar

[23] Morimoto A, Shioda Y, Imamura T, Kudo K, Kawaguchi H, Sakashita K, et al. Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study. Int J Hematol. 2016; 104:99–109. MorimotoA ShiodaY ImamuraT KudoK KawaguchiH SakashitaK Intensified and prolonged therapy comprising cytarabine, vincristine and prednisolone improves outcome in patients with multisystem Langerhans cell histiocytosis: results of the Japan Langerhans Cell Histiocytosis Study Group-02 Protocol Study Int J Hematol 2016 104 99 109 10.1007/s12185-016-1993-327040279 Search in Google Scholar

[24] North American Consortium for Histiocytosis. LCH-IV, International collaborative treatment protocol for children and adolescents with Langerhans cell histiocytosis [Internet]. ClinicalTrials.gov. 2021 [cited 2021 May 9]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02205762 North American Consortium for Histiocytosis LCH-IV, International collaborative treatment protocol for children and adolescents with Langerhans cell histiocytosis [Internet] ClinicalTrials.gov 2021 [cited 2021 May 9]. Available from: https://www.clinicaltrials.gov/ct2/show/NCT02205762 Search in Google Scholar

[25] Minkov M, Grois N, Heitger A, Pötschger U, Westermeier T, Gadner H. Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group. Klin Padiatr. 2000; 212:139–44. MinkovM GroisN HeitgerA PötschgerU WestermeierT GadnerH Treatment of multisystem Langerhans cell histiocytosis. Results of the DAL-HX 83 and DAL-HX 90 studies. DAL-HX Study Group Klin Padiatr 2000 212 139 44 10.1055/s-2000-966710994540 Search in Google Scholar

[26] Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994; 23:72–80. GadnerH HeitgerA GroisN Gatterer-MenzI LadischS Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group Med Pediatr Oncol 1994 23 72 80 10.1002/mpo.29502302038202045 Search in Google Scholar

[27] Wang D-S, Lu M-Y, Yang Y-L, Lin D-T, Lin K-H, Chang H-H, Jou S-T. Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: a single-center, 20-year experience. J Formos Med Assoc. 2021; 120:594–601. WangD-S LuM-Y YangY-L LinD-T LinK-H ChangH-H JouS-T Clinical outcomes of childhood Langerhans cell histiocytosis in Taiwan: a single-center, 20-year experience J Formos Med Assoc 2021 120 594 601 10.1016/j.jfma.2019.12.01932741735 Search in Google Scholar

[28] Stålemark H, Laurencikas E, Karis J, Gavhed D, Fadeel B, Henter J-I. Incidence of Langerhans cell histiocytosis in children: a population-based study. Pediatr Blood Cancer. 2008; 51:76–81. StålemarkH LaurencikasE KarisJ GavhedD FadeelB HenterJ-I Incidence of Langerhans cell histiocytosis in children: a population-based study Pediatr Blood Cancer 2008 51 76 81 10.1002/pbc.2150418266220 Search in Google Scholar

[29] Donadieu J, Rolon M-A, Thomas C, Brugieres L, Plantaz D, Emile JF, et al. Endocrine involvement in pediatric-onset Langerhans’ cell histiocytosis: a population-based study. J Pediatr. 2004; 144:344–50. DonadieuJ RolonM-A ThomasC BrugieresL PlantazD EmileJF Endocrine involvement in pediatric-onset Langerhans’ cell histiocytosis: a population-based study J Pediatr 2004 144 344 50 10.1016/j.jpeds.2003.12.03015001940 Search in Google Scholar

[30] Poompuen S, Chaiyarit J, Techasatian L. Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study. Eur J Pediatr. 2019; 178:771–6. PoompuenS ChaiyaritJ TechasatianL Diverse cutaneous manifestation of Langerhans cell histiocytosis: a 10-year retrospective cohort study Eur J Pediatr 2019 178 771 6 10.1007/s00431-019-03356-130826864 Search in Google Scholar

[31] Zhang X, Zhou J, Chai X, Chen G, Guo B, Ni L, et al. The application of x-ray, computed tomography, and magnetic resonance imaging on 22 pediatric Langerhans cell histiocytosis patients with long bone involvement: a retrospective analysis. Medicine (Baltimore). 2018; 97:e0411. doi: 10.1097/MD.0000000000010411 ZhangX ZhouJ ChaiX ChenG GuoB NiL The application of x-ray, computed tomography, and magnetic resonance imaging on 22 pediatric Langerhans cell histiocytosis patients with long bone involvement: a retrospective analysis Medicine (Baltimore) 2018 97 e0411 10.1097/MD.0000000000010411 594456329702989 Open DOISearch in Google Scholar

[32] Meyer JS, Harty MP, Mahboubi S, Heyman S, Zimmerman RA, Womer RB, et al. Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation. Radiographics. 1995; 15:1135–46. MeyerJS HartyMP MahboubiS HeymanS ZimmermanRA WomerRB Langerhans cell histiocytosis: presentation and evolution of radiologic findings with clinical correlation Radiographics 1995 15 1135 46 10.1148/radiographics.15.5.75018557501855 Search in Google Scholar

[33] Kim JR, Yoon HM, Jung AY, Cho YA, Seo JJ, Lee JS. Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis. Sci Rep. 2019; 9:317. doi: 10.1038/s41598-018-36501-1 KimJR YoonHM JungAY ChoYA SeoJJ LeeJS Comparison of whole-body MRI, bone scan, and radiographic skeletal survey for lesion detection and risk stratification of Langerhans cell histiocytosis Sci Rep 2019 9 317 10.1038/s41598-018-36501-1 634295830670752 Open DOISearch in Google Scholar

[34] Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009; 52:97–101. PhillipsM AllenC GersonP McClainK Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis Pediatr Blood Cancer 2009 52 97 101 10.1002/pbc.2178218951435 Search in Google Scholar

[35] Guo Y, Ning F, Wang G, Li X, Liu J, Yuan Y, Dai P. Retrospective study of Langerhans cell histiocytosis in ear, nose and neck. Am J Otolaryngol. 2020; 41:102369. doi: 10.1016/j.amjoto.2019.102369 GuoY NingF WangG LiX LiuJ YuanY DaiP Retrospective study of Langerhans cell histiocytosis in ear, nose and neck Am J Otolaryngol 2020 41 102369 10.1016/j.amjoto.2019.102369 31870640 Open DOISearch in Google Scholar

[36] Morimoto A, Ikushima S, Kinugawa N, Ishii E, Kohdera U, Sako M, et al.; Japan Langerhans Cell Histiocytosis Study Group. Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study. Cancer. 2006; 107:613–9. MorimotoA IkushimaS KinugawaN IshiiE KohderaU SakoM Japan Langerhans Cell Histiocytosis Study Group Improved outcome in the treatment of pediatric multifocal Langerhans cell histiocytosis: results from the Japan Langerhans Cell Histiocytosis Study Group-96 protocol study Cancer 2006 107 613 9 10.1002/cncr.2198516804933 Search in Google Scholar

[37] Braier JL, Rosso D, Latella A, Chantada G, Ozuna B, Ripoli M, Scopinaro M. Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with “risk-organ” multi-system Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2010; 32:e122–5. doi: 10.1097/MPH.0b013e3181d7acc5 BraierJL RossoD LatellaA ChantadaG OzunaB RipoliM ScopinaroM Importance of multi-lineage hematologic involvement and hypoalbuminemia at diagnosis in patients with “risk-organ” multi-system Langerhans cell histiocytosis J Pediatr Hematol Oncol 2010 32 e122 5 10.1097/MPH.0b013e3181d7acc5 20418784 Open DOISearch in Google Scholar

[38] Totadri S, Bansal D, Trehan A, Srinivasan R, Varma N, Kakkar N, et al. The 5-year EFS of multisystem LCH with risk-organ involvement is suboptimal: a single-center experience from India. J Pediatr Hematol Oncol. 2016; 38:e1–5. doi: 10.1097/MPH.0000000000000414 TotadriS BansalD TrehanA SrinivasanR VarmaN KakkarN The 5-year EFS of multisystem LCH with risk-organ involvement is suboptimal: a single-center experience from India J Pediatr Hematol Oncol 2016 38 e1 5 10.1097/MPH.0000000000000414 26274033 Open DOISearch in Google Scholar

[39] Bernard F, Thomas C, Bertrand Y, Munzer M, Landman Parker J, Ouache M, et al. Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction. Eur J Cancer. 2005; 41:2682–9. BernardF ThomasC BertrandY MunzerM Landman ParkerJ OuacheM Multi-centre pilot study of 2-chlorodeoxyadenosine and cytosine arabinoside combined chemotherapy in refractory Langerhans cell histiocytosis with haematological dysfunction Eur J Cancer 2005 41 2682 9 10.1016/j.ejca.2005.02.00716291085 Search in Google Scholar

[40] Gandolfi L, Adamo S, Pileri A, Broccoli A, Argnani L, Zinzani PL. Multisystemic and multiresistant Langerhans cell histiocytosis: a case treated with BRAF inhibitor. J Natl Compr Canc Netw. 2015; 13:715–8. GandolfiL AdamoS PileriA BroccoliA ArgnaniL ZinzaniPL Multisystemic and multiresistant Langerhans cell histiocytosis: a case treated with BRAF inhibitor J Natl Compr Canc Netw 2015 13 715 8 10.6004/jnccn.2015.008626085387 Search in Google Scholar

[41] Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013; 121:1495–500. HarocheJ Cohen-AubartF EmileJF ArnaudL MaksudP CharlotteF Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation Blood 2013 121 1495 500 10.1182/blood-2012-07-44628623258922 Search in Google Scholar